SETH LERNER to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications SETH LERNER has written about Randomized Controlled Trials as Topic.
Connection Strength
0.490
-
Bladder cancer clinical trials. Urol Oncol. 2005 Jul-Aug; 23(4):275-9.
Score: 0.177
-
Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review. BJU Int. 2012 Sep; 110(5):630-6.
Score: 0.070
-
Neoadjuvant chemotherapy preceding cystectomy for bladder cancer. Expert Opin Pharmacother. 2008 Aug; 9(11):1885-93.
Score: 0.055
-
Neoadjuvant chemotherapy for bladder cancer. Oncology (Williston Park). 2007 Dec; 21(14):1673-81; discussion 1686-8, 1691, 1694.
Score: 0.052
-
Combining surgery and chemotherapy for invasive bladder cancer: current and future directions. Expert Rev Anticancer Ther. 2006 Feb; 6(2):281-91.
Score: 0.046
-
Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. Future Oncol. 2022 Jul; 18(21):2599-2614.
Score: 0.036
-
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Gu?rin-exposed High-risk Non-muscle-invasive Bladder Cancer. Eur Urol. 2022 07; 82(1):34-46.
Score: 0.035
-
Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. Cancer. 2013 Jun 01; 119(11):1994-8.
Score: 0.019